N-Acetyl SS-31: A Research Overview of the Mitochondria-Targeted Peptide

N-acetyl SS-31 is a research-only peptide name for the mitochondria-targeted molecule better known as SS-31 or elamipretide. N-acetyl SS-31 is not FDA-approved for human use in the United States, and no version of the peptide has cleared that bar. Most of the evidence behind it comes from laboratory work and a small number of clinical trials in rare mitochondrial diseases.

The naming gets confusing quickly, because n acetyl ss 31 and plain SS-31 are used interchangeably in forums and product listings. Chemically, the difference is a single acetyl group on one end of the peptide chain, and that detail matters more than most buyers realize.

What Is N-Acetyl SS-31?

SS-31 is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. Researchers also know it as elamipretide, MTP-131, and Bendavia.

The N-acetyl prefix describes an acetyl group attached to the N-terminus, the free end of the peptide chain. Acetylation is a standard chemistry technique that blocks that end and can change a peptide's stability or how cells take it up.

Because of that, a genuinely acetylated peptide is not chemically identical to the SS-31 used in published studies. When a supplier lists n-acetyl SS-31, the certificate of analysis — not the product label — is the only reliable indicator of what is actually in the vial.

How SS-31 Works in the Mitochondria

SS-31 concentrates in mitochondria and binds cardiolipin, a phospholipid found almost exclusively on the inner mitochondrial membrane. Cardiolipin helps hold the electron transport chain together and supports efficient energy production.

When cardiolipin is oxidized during oxidative stress, membranes lose shape and ATP output falls. Preclinical studies suggest SS-31 can stabilize cardiolipin, reduce reactive oxygen species, and improve mitochondrial function in damaged tissue.

Scientists have studied these effects in animal models of heart failure, acute kidney injury, ischemia-reperfusion injury, and neurodegenerative disease. Animal results are encouraging, but they do not prove that the same benefit occurs in humans.

Human Trials and FDA Status

Elamipretide has been tested in people, but it has not been approved by the FDA for any indication. Trial programs have targeted three main conditions:

• Barth syndrome — the TAZPOWER program, which became the focus of a 2024 regulatory decision.
• Primary mitochondrial myopathy — the MMPOWER-3 study, which did not meet its primary endpoints.
• Dry age-related macular degeneration — the ReCLAIM-2 trial, which also fell short on its primary endpoint.

In October 2024, an FDA advisory committee voted against approval for Barth syndrome, citing limited evidence of meaningful clinical benefit. That vote left elamipretide in investigational territory, and as of 2025 the compound remains unapproved for human use.

Reported Benefits and Side Effects

Online interest in this peptide centers on energy, endurance, and recovery from physical stress. Anyone digging into ss-31 peptide benefits and side effects should treat the peer-reviewed literature and vendor marketing as two very different sources of information.

In human trials, reported ss-31 peptide side effects were generally mild and included injection-site reactions, headache, and transient nausea. Serious adverse events were uncommon in the published reports.

What the data actually show breaks down into three tiers:

• Animal data: improved mitochondrial function, lower oxidative stress, and better cardiac or renal outcomes in injury models.
• Human trial data: mixed results, with several functional endpoints that did not reach statistical significance.
• Anecdotal reports: higher energy, faster recovery, and better exercise tolerance, none of which has been verified in controlled research.

Stacking SS-31 With MOTS-c

MOTS-c is a mitochondrial-derived peptide that influences AMPK signaling and metabolic regulation. Because both compounds act on mitochondrial biology, users frequently combine them.

A typical ss-31 and mots-c protocol described online runs SS-31 first for several weeks and then adds MOTS-c. The stated rationale is that restoring membrane lipid structure may make later metabolic signaling more effective.

There is no clinical trial evidence that stacking SS-31 with MOTS-c improves any human health outcome. Questions about the ideal timing between the two compounds also have no evidence-based answer, because the intervals circulating online are user-generated rather than research-derived.

Dosing, Forms, Buying, and Safety

Clinical trials have used subcutaneous injections, typically 40 mg once daily in the Barth syndrome and myopathy studies. That is a protocol figure from research, not a recommended human dose.

An ss-31 peptide nasal spray is marketed by some sellers as a needle-free alternative. Intranasal delivery is far less studied than injection, and nasal absorption is unlikely to match subcutaneous exposure.

Searches for ss-31 peptide buy online return a long list of research-chemical suppliers, and quality varies widely. Third-party certificates of analysis, HPLC purity data, and mass-spec confirmation are the minimum documentation to look for before considering any purchase.

SS-31 is sold as a research chemical rather than a supplement or prescription drug, so FDA manufacturing standards do not apply to most products on the market. Because long-term human safety data are limited, anyone considering the peptide should discuss it with a licensed healthcare professional first — especially people who are pregnant, nursing, taking prescription medication, or managing a chronic condition.

The bottom line: SS-31 is a genuinely interesting mitochondrial research compound, but human evidence remains thin and no form of it is approved for medical use.